Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 2

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

Search:
in the keywords:  hypothyroidism
help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1
Publication available in full text mode
Content available

A retrospective analysis of thyroid dysfunction following multi-modality treatment of head & neck malignancies

100%
Malik J., Sharma A., Monga S., Alam S., Joshi A., Rasool S., Bahadur S.
Polski Przegląd Otorynolaryngologiczny
|
2020
|
vol. 9(3)
17-22
EN
Introduction: The purpose of this study was to determine the incidence of radiation induced hypothyroidism after treatment with radiotherapy alone or in combination with surgery/chemotherapy in head & neck cancer patients. Methods: This study was a retrospective non-randomized trial performed on 100 patients of head & neck cancer in whom definitive radiotherapy, postoperative radiotherapy or radiotherapy in combination with chemotherapy was given. Values of TSH, T3 & T4 were analyzed at baseline and at 6 monthly follow-up. Subclinical hypothyroidism was defined as TSH value of > 4 mU/L and Clinical hypothyroidism was taken as TSH > 10 mU/L with decreased T3 & T4. Results: Out of 100 patients, 73 individuals were euthyroid at the end of 2-year follow-up, 21% had subclinical hypothyroidism and 6% had clinical hypothyroidism. The incidence of subclinical hypothyroidism in the surgery plus radiotherapy group and the radiotherapy group was 22.3% & 50%, respectively. The incidence of clinical hypothyroidism in the surgery plus radio therapy group and the radiotherapy group was 6.5% & nil, respectively. Conclusion: The incidence of hypothyroidism is high in head & neck cancer patients receiving radiotherapy. The risk is higher in patients who undergo surgery in combination with radiotherapy. Regular thyroid function test is, therefore, recommended.
2
Publication available in full text mode
Content available

Hypothyroidism caused by cabozantinib therapy of clear cell renal cell carcinoma – case report, own experience

100%
Buraczewska A., Kardas J., Młot B., Solarek W., Waśko-Grabowska A.
OncoReview
|
2017
|
vol. 7
|
issue 3
121-125
EN
Cabozantinib, the latest available in Poland medication for the treatment of renal cell carcinoma, registered in this indication by the European Medicines Agency (EMA) in September 2016, has been available in several cancer centers in Poland since November 2016 as part of the expanded access program. Primary hypothyroidism is a common complication during thyrosine kinase inhibitors (TKI) treatment, although there are few reports of its occurrence during treatment with cabozantinib, which belongs to this medication group. We present a case of rapid development of clinically apparent hypothyroidism after cabozantinib treatment and report data on this complication in the group of our patients.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.